Compounds > ketobemidone, n,n-dimethyl-3,3-diphenyl-1-methylallylamine drug combination
Page last updated: 2024-09-04

ketobemidone, n,n-dimethyl-3,3-diphenyl-1-methylallylamine drug combination and Neoplasms

ketobemidone, n,n-dimethyl-3,3-diphenyl-1-methylallylamine drug combination has been researched along with Neoplasms in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kjaer, M; Nielsen, H1

Other Studies

1 other study(ies) available for ketobemidone, n,n-dimethyl-3,3-diphenyl-1-methylallylamine drug combination and Neoplasms

ArticleYear
Analgesic effect and bioavailability of oral ketogan given as tablets or mixture to patients with chronic pain of malignant origin.
    Acta oncologica (Stockholm, Sweden), 1988, Volume: 27, Issue:5

    Topics: Administration, Oral; Adult; Aged; Allylamine; Amines; Drug Combinations; Female; Half-Life; Humans; Male; Meperidine; Middle Aged; Neoplasms; Pain, Intractable; Tablets

1988